Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab for Vestibular Migraine
NCT04417361Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Sep 2020
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of galcanezumab in vestibular migraine (VM), sponsored by University of California, San Francisco. Started Sep 2020; status: completed.
02
Drugs
galcanezumab
03
Conditions
vestibular migraine (VM)
Beyond the preview
Go deeper on NCT04417361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04417361.